Clinical Trial: NCT05549037
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hunan Province Tumor Hospital |
| Information Provided By: | Hunan Province Tumor Hospital |
| Last Update Posted: | 2026-06-03 |
Study Overview
Brief Summary
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
Official Title
Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Pembrolizumab, Sintilimab
Other Study ID Numbers
- INJECTION
Start Date (Actual)
2022-09-23
Primary Completion Date (Actual)
2024-12-02
Study Completion Date (Actual)
2026-04-30
Enrollment (Actual)
210
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hunan Province Tumor Hospital |
| Information Provided By: | Hunan Province Tumor Hospital |
| Last Update Posted: | 2026-06-03 |
Study Overview
Brief Summary
This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.
Official Title
Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
Conditions
Non-small Cell Lung Cancer
Intervention / Treatment
- Drug: Pembrolizumab, Sintilimab
Other Study ID Numbers
- INJECTION
Start Date (Actual)
2022-09-23
Primary Completion Date (Actual)
2024-12-02
Study Completion Date (Actual)
2026-04-30
Enrollment (Actual)
210
Study Type
Interventional
Phase
Phase 3